Delhi HC examines pleas to cap Covid test prices
May 03, 2021
‘Ensure sale of Remdesivir in domestic market by all pharma companies’
The Delhi High Court, on Monday, asked the Centre and various pharma majors to respond to a PIL seeking that all drug firms making Remdesivir, used in Covid-19 treatment, be allowed to sell it in the domestic market.
Chief Justice DN Patel and Justice Jasmeet Singh issued notice to the Health Ministry, Central Drugs Standard Control Organisation, Director General of Foreign Trade, and various pharma companies such as Cipla, Zydus and Cadila, seeking their stand on the plea which claims only a handful of such firms are allowed to sell the medicine in the domestic market.
Highlights
The cost of HRCT in the national capital is unregulated and very high beyond what a common man can afford
HRCT has, in the current state of circumstances, become one of the most relevant and vital tests, recommended actively by the doctors for the diagnosis of COVID-19
New Delhi: The Delhi High Court on Monday (May 3) issued a notice to the AAP Govt on a PIL seeking direction to cap the price of High-Resolution Computerised Tomography (HRCT) scan/test which is nowadays massively recommended to people having symptoms of COVID-19.
The PIL urged the High Court to direct the Delhi government to cap the price of High-Resolution Computerised Tomography (HRCT) which is used for detecting the presence and severity of COVID-19 infection in the lungs of patients.